Methods of Detecting and Preventing Atopic Allergic Diseases

Patent metadata

Field	Value
Publication number	US-2025383360-A1
Application number	US-202519046303-A
Country	US
Kind code	A1
Filing date	Feb 5, 2025
Priority date	Dec 22, 2015
Publication date	Dec 18, 2025
Grant date	—

Abstract

The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, and to the prevention of these allergic diseases.

First claim

1 - 22 . (canceled)

23 . A method to identify and treat a subject at risk of developing atopic dermatitis comprising:
a. determining an expression level of thymic stromal lymphopoietin (TSLP) in a non-lesional skin sample from the subject, wherein the skin sample has been obtained by a skin tape stripping method; b. comparing the expression level of TSLP in the skin sample to a control sample wherein a statically significant expression level of TSLP above the expression level of TSLP in the control sample identifies the subject as at risk of developing atopic dermatitis; and c. administering a pharmaceutical composition comprising a TSLP inhibiting agent selected from the group consisting of antibodies that neutralize TSLP action and antibodies that bind to the TSLP receptor and/or a moisturizer for treating atopic dermatitis.

24 . The method of claim 23 , wherein the expression level of TSLP is determined by a method selected from the group consisting of mass spectrometry, Western Blotting, enzyme-linked immunosorbent assay (Elisa) and polymerase chain reaction (PCR).

25 . The method of claim 23 , wherein the skin sample is an epidermal skin sample.

26 . The method of claim 23 , wherein the pharmaceutical composition is administered to the subject by an administration route selected from the group consisting of topical, oral, and subcutaneous.

27 . A method of diagnosing and treating atopic dermatitis in an asymptomatic subject, comprising:
a. determining an expression level of thymic stromal lymphopoietin (TSLP) in a non-lesional skin sample from the subject, wherein the skin sample has been obtained by a skin tape stripping method; b. comparing the expression level of TSLP in the skin sample to a control sample wherein a statically significant-expression level of TSLP above the expression level of TSLP in the control sample identifies the subject as at risk of developing atopic dermatitis; and c. administering an effective amount of a therapeutic for treating atopic dermatitis to the subject identified as at risk of developing atopic dermatitis prior to development of atopic dermatitis symptoms.

28 . The method of claim 27 , wherein the expression level of TSLP is determined by a method selected from the group consisting of mass spectrometry, Western Blotting, enzyme-linked immunosorbent assay (Elisa) and polymerase chain reaction (PCR).

29 . The method of claim 27 , wherein the therapeutic is a topical therapeutic, a systemic therapeutic or a combination thereof.

30 . The method of claim 29 , wherein the topical therapeutic is selected from the group consisting of a moisturizer, topical anti-inflammatory medication, and combinations thereof.

31 . The method of claim 27 , wherein the method further comprises additional administration of the therapeutic upon development of atopic dermatitis symptoms.

32 . The method of claim 27 , wherein the method further comprises administration of a different therapeutic as compared to the therapeutic administered in step c.

33 . The method of claim 27 , wherein the administration of the therapeutic delays the onset of the atopic dermatitis.

34 . The method of claim 27 , wherein administration of the therapeutic reduces the severity of the atopic dermatitis symptoms in the subject.

35 . The method of claim 27 , wherein the skin sample is an epidermal skin sample.

Assignees

• Nat Jewish Health
• Samsung Life Public Welfare Foundation

Inventors

• Leung Donald Y M
• Kim Byung Eui
• Kim Jihyun
• Ahn Kangmo

Classifications

• G01N2800/50

  Determining the risk of developing a disease · CPC title

• G01N2800/24

  Immunology or allergic disorders · CPC title

• G01N2333/52

  Assays involving cytokines · CPC title

• G01N33/6863 Primary

  Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors · CPC title

• G01N33/6881

  from skin · CPC title